Skip to main content
Zanubrutinib Plus Obinutuzumab Granted Accelerated Approval for Follicular Lymphoma
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This is the first approval of a Bruton tyrosine kinase (BTK) inhibitor for FL.   Why it matters: "FL is an indolent subtype of non-Hodgkin's l...
Inotuzumab Ozogamicin Approved for Pediatric Patients with Acute Lymphoblastic Leukemia
Lyn Brook
FDA Updates
The FDA has granted approval to inotuzumab ozogamicin (Besponsa™, Pfizer) for pediatric patients one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).   Why it matters: "Among adult patients with relapsed or refractory B-ALL, the use of inotuzumab ozogamicin has led to improved outcom...
Practice-Changing Proficiency for the Management of Marginal Zone Lymphoma
Lyn Brook
Practice Patterns
Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding new clinical perspectives in the management of marginal zone lymphoma (MZL).   Marginal zone lymphoma comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs). According to the Leukemia and Lymphoma Society®,...
Increasing Knowledge to Improve Patient Outcomes in Multiple Myeloma
Lyn Brook
Practice Patterns
Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding practice-changing strategies for improved patient outcomes in multiple myeloma.   Multiple myeloma is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. ...
Oncology Data Advisor® Appoints Rahul Banerjee, MD, FACP, as Editor in Chief for New Term
Keira Smith
Expert Analysis
Oncology Data Advisor® has appointed Rahul Banerjee, MD, FACP, as Editor in Chief for its next term. Dr. Banerjee is an Assistant Professor of Medicine in the Division of Oncology at the University of Washington, Fred Hutchinson Cancer Center in Seattle, Washington. He specializes in the treatment of multiple myeloma, with research interests in toxicity management, digital health, and the patient experience. 
Bosutinib Approved for Pediatric Patients With Chronic Myelogenous Leukemia
Lyn Brook
FDA Updates
The FDA has approved bosutinib (Bosulif®, Pfizer) for treatment of pediatric patients with newly diagnosed or resistant/intolerant to prior therapy chronic phase (CP) Philadelphia chromosome (Ph)–positive chronic myelogenous leukemia (CML). In addition, the FDA has approved a new capsule dosage available as 50 mg and 100 mg.   Why it matters: ...
Confronting Knowledge Gaps in Rare Hematologic Malignancies
Lyn Brook
Practice Patterns
In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians regarding hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL),...
Elranatamab-bcmm Granted Accelerated Approval for Multiple Myeloma
Lyn Brook
FDA Updates
The FDA granted accelerated approval to elranatamab-bcmm (Elrexfio™, Pfizer, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody. Elranatamab-bcmm is a bispe...
Talquetamab-tgvs Granted Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to talquetamab-tgvs (Talvey™, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.   Why it matters: ...
Glofitamab-gxbm Approved for Relapsed/Refractory Large B-Cell Lymphomas
Keira Smith
FDA Updates
The FDA has approved glofitamab-gxbm (Columvi™, Genentech, Inc.) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma. Patients are required to have undergone two or more previous lines of systemic therapy. Why it matters: "The prognos...
Omidubicel-onlv Approved for Reducing Infection and Time to Neutrophil Recovery in Patients With Hematologic Malignancies
Lyn Brook
FDA Updates
The FDA has approved omidubicel-onlv (Omisirge®, Gamida Cell Ltd.) for treatment of adult and pediatric patients 12 and older with hematologic malignancies, to minimize the time to neutrophil recovery and incidence of infection following myeloablative conditioning for umbilical cord transplantation. Approved population: adults and pediatric pa...
Enhancing Treatment and Patient-Care Proficiency in Multiple Myeloma
Lyn Brook
Practice Patterns
i3 Health has provided a nursing continuing professional development (NCPD)–approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, during which the health care team was challenged to address knowledge gaps experienced in this field. Multiple myeloma (MM) is a B-cell neoplasm characterized by abe...
Pirtobrutinib Granted Accelerated Approval for Mantle Cell Lymphoma
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to pirtobrutinib (Jaypirca™, Eli Lilly and Company) for patients with relapsed or refractory mantle cell lymphoma (MCL) following a minimum of two lines of systemic therapy that included a Bruton tyrosine kinase inhibitor (BTKi). "Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, inhibits bo...
Zanubrutinib Approved for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lyn Brook
FDA Updates
The FDA has approved zanubrutinib (Brukinsa®, BeiGene USA, Inc.) for treatment of chronic lymphocytic leukemia (CLL) and its tissue counterpart, small lymphocytic lymphoma (SLL). "Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed CLL and SLL," wrote Constantine Tam, MD, the Director of Hematolog...
Mosunetuzumab-axgb Approved for Relapsed/Refractory Follicular Lymphoma
Keira Smith
FDA Updates
The FDA has granted accelerated approval to mosunetuzumab-axgb (Lunsumio™, Genentech) for adult patients with relapsed or refractory follicular lymphoma (FL) who have previously received at least two lines of systemic therapy. "Mosunetuzumab is a CD20 x CD3 T-cell–engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant...
Olutasidenib Approved for Acute Myeloid Leukemia
Lyn Brook
FDA Updates
The FDA has granted approval to olutasidenib (Rezlidhia™, Rigel Pharmaceuticals Inc.) for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase 1 gene (IDH1) mutation. Additionally, the FDA granted approval to the Abbott RealTime IDH1 Assay to accurately detect and select pa...
Teclistamab Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Keira Smith
FDA Updates
The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli®, Janssen Biotech) for adult patients with relapsed/refractory multiple myeloma previously treated with four or more lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistimab is the first bispecific B-cell ma...
Enhancing Competence in Evolving Treatment Options for Advanced Hodgkin Lymphoma
Lyn Brook
Practice Patterns
i3 Health has provided an educational activity that has alleviated clinician's knowledge gaps pertaining to the evolving landscape of advanced classical Hodgkin lymphoma (HL). Hodgkin lymphoma is a malignancy involving the lymph nodes and lymphatic system. The American Cancer Society estimated in 2022 that there would be 8,540 new cases of HL in th...
Increasing Expertise for Treatment of Non-Hodgkin Lymphoma
Lyn Brook
Practice Patterns
An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American...
Staying Up to Date on Management of Tumor Lysis Syndrome With Amy Goodrich, MSN, RN, CRNP
Lyn Brook
Expert Analysis
Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected. In this interview, Amy Goodrich, MSN, RN, CRNP, a Nurse Practitioner and Research Nursing Manager at the Johns Hopkins Kimmel Cancer Center, discusses a recent educational activity she co-led, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies.